affin
matur
process
wherebi
immun
system
gener
antibodi
higher
affin
respons
antigen
uniqu
evolutionari
mechan
known
oper
molecul
organ
bodi
deciph
structur
mechan
somat
mutat
antibodi
gene
increas
affin
critic
understand
evolut
immun
repertoir
nextgener
sequenc
ng
allow
reconstruct
antibodi
clonal
lineag
respons
viral
pathogen
possibl
earlier
studi
affin
matur
crystal
structur
antibodi
lineag
bound
target
antigen
reveal
atom
level
antibodi
evolv
penetr
glycan
shield
envelop
glycoprotein
virus
turn
evolv
escap
neutral
collect
structur
studi
affin
matur
shown
increas
antibodi
affin
aris
one
combin
multipl
divers
mechan
includ
improv
shape
complementar
interfac
antigen
increas
buri
surfac
area
upon
complex
format
addit
interfaci
polar
hydrophob
interact
preorgan
rigidif
antigenbind
site
env
env
env
influenza
viru
ha
frontier
immunolog
wwwfrontiersinorg
februari
volum
articl
method
addit
new
method
develop
singlecel
sequenc
allow
largescal
determin
pair
l
h
chain
advanc
conjunct
comput
tool
reconstitut
antibodi
clonal
lineag
provid
genet
record
evolutionari
process
recombin
somat
hypermut
immun
respons
specif
microbi
pathogen
crystal
structur
affinitymatur
germ
line
antibodi
lineag
complex
target
antigen
produc
new
insight
molecular
basi
affin
matur
first
review
understand
basic
biophys
principl
underli
affin
matur
arriv
ng
summar
studi
bulk
b
cell
popul
ng
taught
us
gener
featur
antibodi
repertoir
select
final
discuss
structur
studi
reconstruct
antibodi
clonal
lineag
special
emphasi
immun
respons
far
benefit
applic
ng
singlecel
analysi
better
understand
affin
matur
tabl
advent
ng
number
structur
studi
carri
compar
affinitymatur
antibodi
put
germ
line
precursor
bound
antigen
studi
involv
small
molecul
hapten
phenyloxazolon
nitrophenyl
phosphon
rather
protein
found
somat
mutat
complementaritydetermin
region
cdr
residu
directli
indirectli
implic
bind
hapten
permit
format
addit
hydrogen
bond
electrostat
interact
van
der
waal
contact
particularli
reveal
case
involv
matur
antibodi
bind
nitrophenyl
phosphon
tightli
germ
line
counterpart
larg
chang
conform
antigenbind
site
paratop
observ
upon
hapten
engag
germ
line
antibodi
wherea
free
haptenbound
form
affinitymatur
show
structur
differ
thu
affin
matur
case
appear
driven
larg
mechan
preorgan
paratop
conform
favor
bind
hapten
ligand
conform
preorgan
accompani
decreas
flexibl
paratop
matur
process
may
increas
specif
target
antigen
reduc
possibl
crossreact
antigen
includ
selfantigen
antibodi
matur
process
appear
simultan
select
higher
bind
affin
increas
thermodynam
stabil
studi
matur
antibodi
recogn
small
hapten
somat
mutat
paratop
increas
affin
found
reduc
melt
temperatur
compar
germ
line
precursor
howev
destabil
effect
mutat
compens
addit
somat
mutat
vlvh
interfac
distal
paratop
first
structur
studi
matur
antibodi
respons
protein
antigen
instead
hapten
involv
set
close
relat
antibodi
specif
hen
egg
white
lysozym
hel
antibodi
repres
differ
stage
affin
matur
wherebi
number
somat
mutat
correl
increas
affin
surprisingli
improv
affin
could
attribut
format
addit
hydrogen
bond
salt
bridg
increas
total
buri
surfac
area
instead
affin
matur
result
mainli
burial
increas
amount
hydrophob
surfac
expens
polar
surfac
accompani
improv
shape
complementar
vhhel
interfac
increas
hydrophob
interact
result
highli
correl
structur
rearrang
antibodi
residu
peripheri
interfac
antigen
adjac
central
energet
hot
spot
inde
peripheri
may
offer
suitabl
site
optim
region
typic
flexibl
toler
mutat
central
site
agreement
find
somat
hypermut
spread
structur
divers
gener
v
j
recombin
central
peripher
region
antibodi
bind
site
collect
structur
studi
show
increas
antibodi
affin
small
hapten
model
protein
antigen
hel
aris
one
combin
sever
variabl
includ
addit
interfaci
hydrogen
bond
van
der
waal
contact
conform
preorgan
paratop
improv
shape
complementar
interfac
antigen
increas
burial
total
hydrophob
surfac
area
basic
strategi
well
other
govern
affin
matur
antibodi
respons
biolog
antigen
envelop
glycoprotein
viral
pathogen
discuss
first
summar
ng
bulk
b
cell
popul
taught
us
antibodi
repertoir
select
discuss
recent
insight
affin
matur
gain
structur
studi
antibodi
clonal
lineag
reconstruct
use
ng
tabl
nextgener
sequenc
pair
antibodi
l
h
chain
combin
comput
model
antibodi
structur
use
profil
human
antibodi
repertoir
select
matur
popul
level
exhaust
studi
date
comparison
vlvh
pair
b
cell
vlvh
pair
antigenexperienc
b
cell
isol
human
peripher
blood
show
vl
vh
gene
pair
pure
combinatori
fashion
detect
bias
certain
vlvh
gene
pair
significantli
deplet
enrich
antigenexperienc
repertoir
compar
repertoir
repertoirewid
comput
structur
predict
carri
character
physiochem
properti
antibodi
paratop
wherea
appreci
differ
paratop
hydrophob
solventaccess
surfac
area
evid
antigenexperienc
versu
antibodi
antigenexperienc
amino
acid
sequenc
display
slightli
increas
posit
charg
compar
sequenc
overal
howev
evolutionari
process
somat
hypermut
affin
select
occur
peripheri
blood
leav
distinct
physiochem
imprint
antigenexperienc
antibodi
repertoir
even
level
major
focu
somat
hypermut
contrast
bone
marrow
b
cell
express
antibodi
posit
charg
loop
undergo
preferenti
elimin
discret
development
checkpoint
enter
peripheri
possibl
mechan
reduc
risk
selfreact
studi
determin
whether
ng
could
use
detect
antigenspecif
sequenc
bulk
b
cell
popul
analysi
ident
sequenc
share
individu
previous
vaccin
haemophilu
influenza
type
b
identifi
number
sequenc
known
specif
bacterium
conserv
sequenc
also
observ
patient
recov
acut
dengu
infect
indic
converg
antibodi
evolut
differ
individu
expos
antigen
anoth
studi
ng
singlecel
sort
peripher
blood
plasmablast
use
profil
acut
antibodi
respons
influenza
vaccin
antibodi
abl
neutral
viru
select
bioinformat
clonal
famili
vaccineinduc
antibodi
contain
averag
somat
mutat
overal
notabl
antibodi
exhibit
higher
affin
hemagglutinin
prior
year
influenza
strain
ha
immun
strain
suggest
recal
memori
b
cell
express
antibodi
previous
undergon
affin
matur
nextgener
sequenc
coupl
bioinformat
analysi
allow
first
time
reconstruct
antibodi
clonal
lineag
infer
germ
line
progenitor
sequenc
neither
possibl
earlier
studi
affin
matur
howev
import
caveat
germ
line
sequenc
predict
sequenc
may
differ
true
unmut
ancestor
sequenc
wherea
mutat
vl
vh
gene
segment
identifi
high
confid
origin
vljl
especi
vhdjh
junction
sequenc
germ
line
antibodi
uncertain
particular
imposs
know
insert
delet
sequenc
took
place
v
j
recombin
introduc
b
cell
affin
matur
consequ
statist
method
must
use
infer
like
unmut
common
ancestor
align
set
sequenc
taken
clonal
relat
measur
surfac
plasmon
reson
spr
put
germ
line
precursor
antibodi
recogn
subunit
envelop
glycoprotein
env
bound
recombin
lower
affin
matur
antibodi
kd
versu
nm
micromolar
kd
also
report
germ
line
precursor
broadli
neutral
antibodi
bnab
recogn
quaternari
epitop
subunit
env
although
seemingli
low
affin
nevertheless
suffici
trigger
affin
matur
unmut
b
cell
vivo
contrast
put
germ
line
ancestor
sever
bnab
specif
bind
site
env
fail
show
detect
bind
recombin
env
rais
question
b
cell
matur
lead
eventu
product
bnab
initi
moreov
failur
observ
even
though
amino
acid
sequenc
v
j
junction
affinitymatur
antibodi
left
unchang
reconstruct
germ
line
version
one
possibl
matur
bind
site
bnab
precursor
trigger
nonhiv
antigen
result
antibodi
intermedi
serendipit
crossreact
env
like
howev
interact
protein
solut
affin
measur
spr
relat
techniqu
differ
contact
two
cell
cell
viru
affin
exampl
wherea
spr
unabl
detect
bind
mhc
class
ii
affin
mhc
class
ii
b
cell
could
measur
use
support
lipid
bilay
therefor
physiolog
condit
germ
line
precursor
bind
site
bnab
express
surfac
b
cell
might
engag
membraneanchor
env
virion
surfac
surfac
infect
cell
suffici
affin
trigger
b
cell
matur
support
idea
germ
line
precursor
sever
antiinfluenza
ha
bnab
found
bind
ha
present
membran
form
cell
surfac
igm
solubl
igg
precursor
detect
affin
ha
follow
section
select
repres
exampl
affin
matur
c
closeup
interfac
germ
line
precursor
peptid
vicin
vh
green
magenta
affinitymatur
mutat
result
format
bident
salt
bridg
vh
teal
residu
visibl
c
due
disord
cterminu
peptid
order
illustr
multipl
structur
strategi
antibodi
employ
increas
potenc
breadth
pathogen
neutral
antibodi
isol
particip
hiv
vaccin
efficaci
trial
like
bnab
elicit
respons
infect
highli
mutat
structur
affinitymatur
complex
env
peptid
show
bnab
target
residu
site
vaccineinduc
immun
pressur
structur
also
determin
put
germ
line
precursor
unligand
form
bound
peptid
comparison
structur
reveal
affin
matur
driven
format
two
new
salt
bridg
link
respect
figur
addit
unbound
germ
line
precursor
adopt
differ
conform
complex
impli
flexibl
contrast
conform
complex
nearli
ident
unbound
matur
preorgan
paratop
configur
suitabl
bind
accompani
rigidif
lower
entrop
cost
complex
format
contribut
affin
increas
matur
paratop
preorgan
rigidif
also
describ
lineag
antiinfluenza
viru
ha
antibodi
underscor
gener
util
mechan
improv
affin
relat
studi
use
hydrogendeuterium
exchang
combin
mass
spectrometri
hdxm
investig
affin
matur
alter
dynam
bnab
env
importantli
high
variabl
constantli
evolv
natur
env
distinguish
conform
dynam
glycoprotein
static
model
antigen
use
studi
affin
matur
prior
ng
hdxm
directli
measur
local
protein
dynam
monitor
backbon
amid
deuterium
uptak
protein
dilut
solut
dynam
region
protein
take
deuterium
rapidli
stabl
region
hdxm
use
compar
local
dynam
predict
germ
line
affinitymatur
form
two
bnab
specif
bind
site
env
case
paratop
matur
bnab
less
dynam
overal
germ
line
counterpart
agreement
previou
evid
paratop
becom
rigid
matur
process
surprisingli
howev
largest
decreas
dynam
occur
peripheri
paratop
site
adjac
env
glycan
rather
primari
envcontact
site
similar
pattern
observ
bnab
specif
quaternari
epitop
env
stabil
paratop
peripheri
may
serv
minim
potenti
clash
nearbi
env
glycan
maintain
critic
bind
interact
mediat
center
paratop
probabl
coincident
similar
focu
affin
matur
site
peripher
rather
central
interfac
antigen
also
observ
antihel
antibodi
antibodi
lineag
block
bind
site
via
interact
domin
affin
matur
associ
mutat
contact
noncontact
residu
includ
framework
fr
residu
distant
interfac
env
structur
analysi
put
germ
line
precursor
two
intermedi
matur
pathway
reveal
shift
rel
orient
vl
vh
domain
evolut
lineag
correspond
root
mean
squar
deviat
posit
figur
shift
mediat
sever
mutat
vlvh
interfac
includ
leucinetovalin
substitut
fr
posit
contribut
reorient
vl
domain
also
reconfigur
figur
although
import
mutat
neighbor
mutat
also
locat
vl
vh
interfac
may
contribut
vlvh
reorient
like
vlvh
reorient
occur
respons
insert
loop
env
infect
allow
viru
escap
neutral
progenitor
displac
vl
away
allow
accommod
insert
without
steric
hindranc
addit
conform
germ
line
precursor
incompat
bind
least
observ
complex
therebi
necessit
rearrang
loop
matur
process
sharp
contrast
bnab
highli
mutat
potent
human
antimiddl
east
respiratori
syndrom
coronaviru
antibodi
almost
germ
line
one
somat
mutat
h
chain
structur
complex
merscov
receptorbind
domain
show
h
chain
contribut
bind
surfac
subnanomolar
affin
despit
near
absenc
somat
mutat
result
direct
interact
germ
lineencod
vh
framework
region
residu
recombinationgener
residu
vhdjh
junction
like
antiinfluenza
ha
bnab
use
vh
gene
segment
viru
neutral
depend
sole
h
chain
seven
somat
mutat
requir
maximum
affin
systemat
dissect
contribut
mutat
fr
residu
affin
matur
deep
mutat
scan
appli
antivascular
endotheli
cell
growth
factor
antibodi
number
fr
mutat
posit
distal
cdr
found
improv
affin
andor
thermost
particular
fr
mutat
away
antigenbind
site
increas
affin
stabil
alter
orient
constant
domain
cl
rel
vl
vh
well
orient
vl
vh
measur
hdxm
mutat
modul
interdomain
conform
dynam
antibodi
furthermor
analysi
human
vl
sequenc
show
somat
mutat
occur
frequent
posit
strongli
suggest
biolog
relev
repertoir
select
figur
differenti
glycan
recognit
affinitymatur
antibodi
posit
complementaritydetermin
region
cdr
loop
wheat
matur
antibodi
envelop
glycoprotein
env
vl
cdr
loop
label
vh
cdr
loop
label
green
red
region
depict
molecular
surfac
glycan
drawn
sphere
label
epitop
compos
glycan
b
posit
cdr
loop
yellow
matur
antibodi
env
epitop
compos
well
four
glycan
c
yellow
contact
glycan
wheat
contact
glycan
due
shift
posit
rel
besid
high
sequenc
variabl
anoth
featur
env
distinguish
model
antigen
hel
use
previou
studi
affin
matur
glycosyl
inde
extens
nglycosyl
mask
much
env
protein
surfac
antibodi
recognit
nevertheless
number
potent
bnab
discov
penetr
glycan
shield
engag
carbohydr
protein
antigen
determin
thoroughli
studi
exampl
date
famili
bnab
shown
bind
nglycan
locat
highmannos
patch
center
highli
conserv
glycan
protein
element
base
loop
reveal
ng
xray
crystallographi
put
germ
line
precursor
famili
split
two
evolutionari
branch
differ
consider
interact
env
glycan
figur
b
one
branch
exemplifi
contact
glycan
wherea
branch
exemplifi
also
contact
glycan
employ
common
set
cdr
residu
contact
glycan
loop
nearli
also
found
germ
line
precursor
conserv
suggest
critic
event
trigger
antibodi
respons
simultan
recognit
carbohydr
protein
determin
antibodi
share
similar
bind
site
architectur
long
loop
pack
entir
length
glycan
therebi
penetr
glycan
shield
reach
env
protein
surfac
figur
antibodi
well
germ
line
precursor
close
face
one
side
paratop
engag
glycan
second
open
face
differ
open
face
enabl
avoid
neighbor
glycan
shift
away
equival
posit
figur
contrast
mutat
affin
matur
result
product
interact
glycan
agreement
structur
data
delet
glycan
abolish
neutral
nearli
isol
wherea
delet
neighbor
glycan
littl
effect
convers
less
reliant
glycan
viru
neutral
abil
util
altern
glycan
achiev
highaffin
bind
figur
role
insert
antibodi
affin
matur
insert
five
amino
acid
vh
framework
region
matur
antibodi
enabl
extend
glycan
envelop
glycoprotein
env
contact
protein
beneath
glycan
shield
vh
vl
magenta
cyan
respect
insert
red
env
yellow
drawn
molecular
surfac
glycan
repres
blue
stick
recent
ng
longitudin
cohort
perform
investig
coevolut
env
antibodi
target
glycoprotein
identifi
viral
variant
initi
matur
bnab
studi
shown
viral
escap
gener
pool
divers
epitop
variant
somat
hypermut
act
parallel
creat
antibodi
differenti
abil
neutral
variant
thu
antibodi
lineag
isol
independ
two
differ
infect
african
patient
target
apex
epitop
env
trimer
crystal
structur
bnab
isol
month
postinfect
show
somat
mutat
loop
adopt
conform
project
cdr
extend
conform
anion
charact
contain
least
one
sulfotyrosin
probabl
enabl
loop
penetr
glycan
shield
apex
epitop
contact
posit
charg
protein
surfac
env
trimer
moreov
donor
env
glycoform
heterogen
may
play
role
activ
b
cell
precursor
lineag
allow
germ
line
antibodi
bind
earli
env
trimer
form
lack
complex
hybrid
glycan
key
posit
accord
polyreact
hypothesi
b
cell
initi
produc
germ
line
antibodi
conform
flexibl
combin
site
abl
recogn
divers
antigen
low
affin
way
immun
system
respond
enorm
varieti
potenti
antigen
whose
number
dwarf
theoret
estim
clonal
divers
germ
line
antibodi
describ
earlier
studi
immun
respons
hapten
model
protein
env
shown
affin
matur
gener
antibodi
higher
affin
specif
germ
line
antibodi
least
part
rigidif
paratop
howev
recent
studi
glycanspecif
antibodi
suggest
altern
pathway
antibodi
evolut
distinct
polyreact
germ
line
pathway
combin
glycan
microarray
molecular
dynam
md
simul
use
investig
affin
matur
two
antibodi
specif
gangliosid
tumorassoci
carbohydr
antigen
overexpress
variou
cancer
notabl
neuroblastoma
melanoma
surprisingli
put
germ
line
antibodi
although
lower
affin
matur
counterpart
highli
select
matur
antibodi
screen
hundr
glycan
thousand
protein
possibl
reason
lack
observ
polyreact
investig
md
simul
germ
line
affinitymatur
simul
reveal
rather
becom
rigid
bind
site
matur
antibodi
show
increas
flexibl
rel
bind
site
germ
line
antibodi
like
affin
matur
enthalp
driven
increas
direct
watermedi
hydrogen
bond
rather
entrop
driven
decreas
bind
site
flexibl
high
select
germ
line
antibodi
gangliosid
compar
polyreact
antibodi
antigen
may
reduc
risk
develop
autoimmun
diseas
syndrom
associ
antibodi
structur
relat
gangliosid
multibas
infram
indel
introduc
somat
hypermut
germin
center
b
cell
along
point
mutat
reveal
ng
frequenc
indel
among
total
somat
mutat
normal
human
b
cell
repertoir
low
sharp
contrast
bnab
env
contain
indel
rang
size
amino
acid
indel
primari
mean
antibodi
effect
larg
chang
steric
volum
compar
associ
addit
remov
glycan
inde
role
indel
bnab
matur
accommod
glycan
penetr
glycan
shield
andor
increas
number
interfaci
contact
distinguish
featur
bnab
target
bind
site
env
delet
two
six
amino
acid
function
delet
avoid
steric
clash
glycan
loop
revers
delet
germ
line
markedli
diminish
bind
notabl
delet
appear
across
multipl
lineag
bnab
differ
individu
suggest
viabl
solut
fit
antibodi
bind
site
env
structur
antibodi
complex
trimer
env
show
bnab
recogn
epitop
span
env
subunit
insert
five
amino
acid
extend
glycan
establish
product
interact
glycan
enabl
penetr
glycan
shield
contact
protein
surfac
env
figur
like
bnab
bind
trimer
env
interfac
insert
eight
amino
acid
project
cleft
env
subunit
result
addit
stabil
contact
antigen
increas
neutral
potenc
matur
antibodi
compar
germ
line
precursor
structur
studi
antibodi
affin
matur
span
nearli
year
identifi
divers
biophys
mechan
underli
prototyp
exampl
molecular
evolut
includ
improv
shape
complementar
interfac
antigen
increas
buri
surfac
area
upon
complex
format
addit
interfaci
polar
hydrophob
interact
preorgan
rigidif
antigenbind
site
vlvh
reorient
last
year
ng
allow
reconstruct
antibodi
clonal
lineag
immun
respons
viral
pathogen
mainli
possibl
previous
remark
studi
reveal
antibodi
evolv
penetr
glycan
shield
env
viru
turn
evolv
escap
neutral
new
insight
coevolut
virus
antivir
antibodi
come
ng
env
variant
antibodi
target
variant
welldocu
longitudin
cohort
african
patient
demonstr
recent
although
far
primari
focu
studi
use
ng
singlecel
analysi
identifi
germ
line
progenitor
intermedi
along
antibodi
matur
pathway
futur
applic
method
pathogen
dengu
viru
ebola
viru
undoubtedli
uncov
new
structur
strategi
gener
highaffin
binder
bolster
host
immun
defens
becom
increasingli
evid
contribut
somat
hypermut
bnab
develop
must
consid
design
vaccin
immunogen
differ
viral
pathogen
one
extrem
bnab
virus
merscov
hepat
c
viru
appear
exist
natur
rel
somat
mutat
importantli
somat
mutat
found
requir
bind
germ
line
ancestor
bnab
viral
target
may
facilit
elicit
effect
vaccin
respons
extrem
bnab
virus
highli
somat
mutat
gener
requir
year
develop
infect
individu
furthermor
germ
line
precursor
bnab
often
exhibit
littl
detect
affin
env
make
elicit
antibodi
vaccin
formid
challeng
current
strategi
overcom
roadblock
involv
initi
activ
matur
b
cell
express
germ
line
b
cell
receptor
engin
germ
linebind
immunogen
follow
sequenti
vaccin
immunogen
design
bind
intermedi
antibodi
order
guid
immun
system
complex
matur
pathway
ultim
lead
antibodi
specif
somat
mutat
confer
high
affin
neutral
potenc
rm
conceiv
wrote
manuscript
studi
support
nation
institut
health
grant
rm
